Atorvastatin reduced soluble receptors of tnf-alpha in systemic lupus erythematosus

Página do item simplificado
dc.contributor.authorFerreira, G. A.
dc.contributor.authorTeixeira, A. L.
dc.contributor.authorCalderaro, D. C.
dc.contributor.authorSato, E. I. [UNIFESP]
dc.date.accessioned2019-01-21T10:30:07Z
dc.date.available2019-01-21T10:30:07Z
dc.date.issued2016
dc.description.abstractObjective The aim of this study was to evaluate the efficacy of atorvastatin to reduce the plasma levels of TNF system molecules (TNF-alpha, sTNFR1 and sTNFR2) and to assess their association with risk factors for accelerate atherosclerosis and clinical disease activity scores in SLE patients. Methods In a previous study, 64 female SLE patients received 20 mg/day of atorvastatin and 24 SLE patients (non-treated group) were followed for 8 weeks. Plasma levels of TNF-alpha, sTNFR 1 and sTNFR 2 were measured by ELISA, at baseline and at the end of the study. Results The plasma levels of sTNFR1 and sTNFR 2 showed a positive correlation with SLEDAI score. We also found a positive correlation between TNF-alpha and sTNFR 1 levels and SLICC score. Patients with current nephritis and patients with anti-dsDNA antibodies presented higher sTNFR1 and sTNFR2 levels. Patients with abdominal obesity and arterial hypertension also had higher plasma levels of soluble receptors. At the end of 8 weeks, we observed a significant decrease in sTNFR1 plasma levels in patients receiving atorvastatin [median (percentile), 876.5 (717-1284 pg/ml) vs. 748 (629.6-917.3 pg/ml), p=0.03], without difference regarding TNF-alpha and sTNFR2 plasma levels. The SLEDAI and SLICC scores were independent determinants of the plasma levels of sRTNF1. Conclusion Atorvastatin reduced soluble receptors of TNF-alpha. The plasma levels of TNF-alpha, sTNFR1 and sTNFR2 may play a role in SLE activity and atherosclerosis, and might be evaluated as targets for new therapies.en
dc.description.affiliationDepartment of Locomotor System, Medical School, Universidade Federal de Minas Gerais; and Rheumatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
dc.description.affiliationDepartment of Internal Medicine, Medical School, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
dc.description.affiliationRheumatology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
dc.description.affiliationRheumatology Division, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brazil
dc.description.affiliationUnifespRheumatology Division, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCNPq
dc.description.sponsorshipFapemig
dc.format.extent42-48
dc.identifierhttp://www.clinexprheumatol.org/abstract.asp?a=9060
dc.identifier.citationClinical And Experimental Rheumatology. Pisa, v. 34, n. 1, p. 42-48, 2016.
dc.identifier.issn0392-856X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49591
dc.identifier.wosWOS:000371850400007
dc.language.isoeng
dc.publisherClinical & exper rheumatology
dc.relation.ispartofClinical And Experimental Rheumatology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectSystemic Lupus Erythematosusen
dc.subjectAtherosclerosisen
dc.subjectReceptorsen
dc.subjectTumour Necrosis Factoren
dc.subjectAtorvastatinTumor-Necrosis-Factoren
dc.subjectDisease-Activityen
dc.subjectProinflammatory Cytokinesen
dc.subjectInsulin-Resistanceen
dc.subjectTherapyen
dc.subjectRisken
dc.subjectExpressionen
dc.subjectStatinsen
dc.subjectMarkersen
dc.subjectSleen
dc.titleAtorvastatin reduced soluble receptors of tnf-alpha in systemic lupus erythematosusen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos